Immunoassay of prostate-specific antigen (PSA) using resonant frequency shift of piezoelectric nanomechanical microcantilever

被引:163
|
作者
Lee, JH
Hwang, KS
Park, J
Yoon, KH
Yoon, DS
Kim, TS [1 ]
机构
[1] KIST, Microsyst Res Ctr, Seoul 136791, South Korea
[2] Yonsei Univ, Dept Ceram Engn, Seoul 120749, South Korea
关键词
nanomechanics; PSA; piezoelectric; PZT cantilever; quantitative analysis; protein mass detection;
D O I
10.1016/j.bios.2004.09.024
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We designed and fabricated the nanomechanical Pb(Zr0.52Ti0.48)O-3 (PZT) cantilever; we demonstrated a novel electrical measurement, under a controlled ambient temperature and humidity, for label-free detection of a prostate-specific antigen (PSA); and we achieved a detection sensitivity as low as 10 pg/ml. For the fabrication of our nanomechanical PZT cantilevers, we used composite layers of Ta/Pt/PZT/Pt/SiO2 On a SiNx supporting layer for electrical self-sensing without external oscillators. This method allows PSA proteins to be detected via a simple electrical measurement of the resonant frequency change generated by the molecular interaction of the antigen (Ag) and the antibody (Ab). The resonant frequency shifted due to the specific binding of the PSA Ag to its Ab which is immobilized via calixcrown self-assembled monolayers on an Au surface deposited on a nanomechanical PZT cantilever. We determined the resonant frequency shift as the value of -172 Hz and -273 Hz, when the concentration of PSA Ag was 1 ng/ml, with the cantilever dimensions of 100 mu m x 300 mu m and 50 mu m x 150 mu m, respectively. Theoretical and experimental analysis suggests that the minimum detectable sensitivity for a resonant frequency shift due to a PSA Ag-Ab interaction depends on the dimensions of the nanomechanical PZT cantilever. These results also demonstrate that the experimentally measured resonant frequency shift is larger than that calculated theoretically due to the compressive stress of the PSA Ag-Ab interaction. (c) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:2157 / 2162
页数:6
相关论文
共 50 条
  • [1] Prostate-specific antigen (PSA) in human seminal plasma
    Schieferstein, G
    ARCHIVES OF ANDROLOGY, 1999, 42 (03): : 193 - 197
  • [2] Development of ultra-high sensitivity bioluminescent enzyme immunoassay for prostate-specific antigen (PSA) using firefly luciferase
    Seto, Y
    Iba, T
    Abe, K
    LUMINESCENCE, 2001, 16 (04) : 285 - 290
  • [3] Individual prostate-specific antigen (PSA) forms as prostate tumor markers
    Becker, C
    Lilja, H
    CLINICA CHIMICA ACTA, 1997, 257 (01) : 117 - 132
  • [4] Prostate-specific antigen (PSA) and radiotherapy in locally confined prostate cancer
    Schaefer, U
    Micke, O
    Willich, N
    ANTICANCER RESEARCH, 1999, 19 (4A) : 2645 - 2648
  • [5] Association of sociodemographic factors and prostate-specific antigen (PSA) testing
    Gorday, William
    Sadrzadeh, Hossein
    de Koning, Lawrence
    Naugler, Christopher
    CLINICAL BIOCHEMISTRY, 2014, 47 (16-17) : 164 - 169
  • [6] Patient knowledge about prostate-specific antigen (PSA) and prostate cancer in Australia
    Pan, David
    McCahy, Philip
    BJU INTERNATIONAL, 2012, 109 : 52 - 56
  • [7] Free and complexed prostate-specific antigen (PSA) in the early detection of prostate cancer
    Tello, FL
    Prats, CH
    González, MDD
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (02) : 116 - 120
  • [8] The use of prostate-specific antigen (PSA) for the monitoring of radiation therapy in prostate cancer
    Schafer, U
    Micke, O
    Hampel, G
    Brandt, B
    Bovenschulte, A
    Semjonow, A
    Willich, N
    ANTICANCER RESEARCH, 1997, 17 (4B) : 2983 - 2986
  • [9] Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA)
    Ceriani, L
    Giovanella, L
    Salvadore, M
    Bono, AV
    Roncari, G
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1997, 12 (01) : 27 - 34
  • [10] Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
    D Connolly
    A Black
    L J Murray
    T Nambirajan
    P F Keane
    A Gavin
    Prostate Cancer and Prostatic Diseases, 2009, 12 : 47 - 51